Exploring a new surgical method for Alzheimer's Disease
An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease
NA · Affiliated Hospital of Jiangnan University · NCT06448975
This study is testing a new surgery to see if it can help improve memory and daily life for older adults with Alzheimer's by clearing harmful proteins from the brain.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 60 Years to 80 Years |
| Sex | All |
| Sponsor | Affiliated Hospital of Jiangnan University (other) |
| Locations | 1 site (Wuxi, Jiangsu) |
| Trial ID | NCT06448975 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of deep cervical lymphovenous bypass as a potential treatment for Alzheimer's Disease (AD). It focuses on improving lymphatic circulation to facilitate the clearance of amyloid-beta and tau proteins, which are implicated in the pathology of AD. Participants aged 60 to 80 with a diagnosis of mild to severe AD will undergo this surgical intervention, with the aim of enhancing cognitive function and quality of life. The study seeks to provide a novel approach to treating a condition that currently lacks effective therapies.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 60 to 80 who have been diagnosed with mild to severe Alzheimer's Disease for more than 12 months.
Not a fit: Patients with severe systemic diseases, those unable to tolerate general anesthesia, or pregnant women may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could offer a new surgical treatment option that improves cognitive function and quality of life for patients with Alzheimer's Disease.
How similar studies have performed: While this approach is novel, recent studies have begun to explore the role of the glymphatic system in Alzheimer's Disease, indicating potential for success in similar methodologies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The age ranged from 60 to 80 years, and the time from initial diagnosis to enrollment was more than 12 months 2. The estimated survival time is more than 12 months; 3. The clinically diagnosed patients with mild to severe Alzheimer's Disease; 4. The imaging examination has the correlation diagnosis evidence; 5. Volunteer to participate in the project and sign an informed consent form with the guardian. Exclusion Criteria: 1. Complicated with other severe systemic underlying diseases; 2. Unable to tolerate general anesthesia; 3. The pregnant women; 4. Recent severe infection or infectious diseases within 4 weeks; 5. Unable to complete the evaluator or refused to complete the one-year clinical follow-up. 6. Refusal to participate
Where this trial is running
Wuxi, Jiangsu
- Affiliated Hospital of Jiangnan University — Wuxi, Jiangsu, China (RECRUITING)
Study contacts
- Study coordinator: Lu Hua
- Email: luhua1969@hotmail.com
- Phone: 08615301516197
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer Disease, Deep Cervical Lymphovenous Bypass